Cancer immunotherapy, bladder cancer research, and clinical innovation by CG Oncology

CG Oncology, Inc. has published results from its Phase 3 BOND-003 Cohort C clinical trial in The Lancet Oncology. The peer-reviewed study focuses on evaluating complete response rates, duration ...

CG Oncology, Inc. has named David Fela as its new vice president of analytical development and quality control. The appointment comes as the company advances its clinical programs with a focus ...

CG Oncology, Inc. announced that its Chairman, President and Chief Executive Officer Arthur Kuan will participate in fireside chats at both the Jefferies Global Healthcare Conference and the ...

CG Oncology, Inc. is participating at the AUA26 conference, engaging directly with leading figures in the urology and uro-oncology communities. The company aims to build partnerships and foster ...

CG Oncology, Inc. has announced its planned participation at the upcoming American Urological Association Annual Meeting, where it will present initial results from its CORE-008 Cohort CX study in ...

CG Oncology, Inc. released its financial results for the first quarter ended March 31, 2026 and announced updates to its business operations. The company, which focuses on urology and therapies ...

Approximately 75 percent of new bladder cancer cases are diagnosed as non–muscle-invasive bladder cancer, according to CG Oncology, Inc. The company notes that even with approved therapies, ...

CG Oncology, Inc. has presented five new research posters focused on cretostimogene at the ASCO Genitourinary Cancers Symposium in San Francisco. The posters draw from studies including ...